Vyome Holdings, Inc. — requested filing identity does not match source
The supplied filing is ReShape Lifesciences Inc.’s Form 10-Q, ticker RSLS, for the quarter ended September 30, 2023—not a filing identified as Vyome Holdings, Inc. The summary below describes the filing provided.
Business context and reporting period
ReShape sells the Lap-Band adjustable gastric banding system and operates in the United States, Australia, Europe, and other markets. The filing says Lap-Band accounted for nearly all revenue and gross profit; ReShapeCare revenue was minimal, while the DBSN device remained in development and generated no revenue. Figures below are in U.S. dollars; financial statement amounts are in thousands unless stated otherwise.
Key financial metrics
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $2.155m | $2.798m | $6.696m | $8.130m |
| Gross profit / margin | $1.288m / 59.8% | $2.101m / 75.1% | $3.706m / 55.3% | $5.202m / 64.0% |
| Operating loss | $(3.880)m | $(12.301)m | $(13.488)m | $(29.658)m |
| Net loss | $(3.534)m | $(12.186)m | $(9.689)m | $(29.745)m |
| Adjusted EBITDA loss (non-GAAP) | $(2.905)m | $(4.248)m | $(11.980)m | $(19.202)m |
| Operating cash used | Not provided for quarter | Not provided for quarter | $(14.503)m | $(19.073)m |
At September 30, 2023, cash and cash equivalents were $1.449m, restricted cash was $0.100m, and accounts receivable was $2.153m. Net working capital was approximately $2.9m. Total assets were $7.827m and total liabilities were $4.744m. The balance sheet shows no conventional borrowing balance; liabilities included operating lease obligations of $0.285m and a $0.100m warrant liability, in addition to current operating liabilities.
Material changes versus comparable periods
- Q3 revenue decreased 23.0% year over year; nine-month revenue fell 17.6%. Management attributed the declines principally to lower sales volume, particularly in the United States, with declines also in Australia and Europe.
- Gross margin contracted to 59.8% in Q3 from 75.1%, and to 55.3% for the nine months from 64.0%. Management cited lower sales and additional overhead/fixed costs.
- Operating expenses fell substantially, including lower marketing, general and administrative, and research and development costs. Comparisons also reflect a much smaller impairment charge in 2023: $0.777m versus $7.429m in 2022. The 2022 impairment included the ReShape Vest program after the company stopped its clinical trials.
- Cash used in operations improved to $14.503m from $19.073m for the nine-month period, but cash and restricted cash declined by $2.406m during 2023. Financing activities provided $12.113m, primarily from 2023 securities offerings.
- Common shares issued and outstanding at September 30 were 3,452,841, compared with 519,219 at year-end 2022. The filing reports 13,135,478 shares outstanding as of November 3, 2023, following subsequent financing activity and warrant-related issuances. A 1-for-50 reverse split effective December 2022 is reflected retrospectively in share data.
Outlook, risks, contingencies, and unusual items
- Going concern: The company said revenue does not cover operating costs and that available cash may not fund operations for more than 12 months from the filing date. Management concluded substantial doubt exists about the company’s ability to continue as a going concern; its financing and operating plans were not considered probable enough to alleviate that doubt. Additional financing may not be available on acceptable terms.
- Management outlook: Management expected targeted digital marketing and demand-generation efforts to support revenue growth in Q4 2023 and early 2024. It anticipated FDA approval of LAP-BAND 2.0 in early 2024 and expected a launch, if approved, to support sales. These are forward-looking expectations, not assurances.
- Post-quarter financing: On October 3, 2023, the company completed an offering of common stock, warrants exercisable at $0.33 per share, and pre-funded warrants; reported net proceeds were approximately $2.8m. It also repriced certain existing warrants to $0.33. This financing creates significant potential dilution.
- Workforce reduction: On November 3, 2023, the company announced a workforce reduction of approximately 23%, with projected annualized savings of approximately $1.2m.
- Impairments and warrant valuation: Q3 included a $0.777m non-cash impairment charge, including impairment of remaining finite-lived intangible assets to zero. A $3.850m nine-month gain from changes in the fair value of liability warrants reduced reported net loss but is non-cash.
- Litigation: A court judgment for Cowen included $1.35m plus interest and $675,000 of attorneys’ fees. By September 30, the company had paid the judgment and the first $275,000 fee installment; $400,000 of fees remained accrued.
- Internal controls: Management concluded internal control over financial reporting was not effective at September 30 due to material weaknesses involving accounting resources, purchase accounting, income taxes, journal-entry approval/segregation of duties, and IT access/change management. Remediation was underway.
- Other risks: The company stated it may reduce marketing, clinical, or product-development spending depending on cash availability. It also cited regulatory, clinical-development, market-acceptance, competition, intellectual-property, and international operating risks.
Most important facts for investors to verify
- Confirm the issuer: the supplied Form 10-Q is for ReShape Lifesciences Inc. (RSLS), not Vyome Holdings, Inc.
- Review the going-concern disclosure and assess cash runway, operating cash burn, and the availability and terms of future financing.
- Evaluate the October 2023 offering, warrant repricing, and resulting actual and potential share dilution.
- Track Lap-Band sales, gross-margin recovery, and whether LAP-BAND 2.0 receives FDA approval on management’s anticipated timetable.
- Monitor remediation of the disclosed material weaknesses and any subsequent reporting or restatement developments.
- Reconcile the filing’s cash-flow narrative, which refers to a $8.9m net loss for the nine-month period, with the financial statements’ reported net loss of $9.689m.